We found that in the ADAR1-down or ADAR1-up group of HCC patients, 3 out of 6 (50%) or 6 out of 11 (54.5%) showed ≥ 2-fold decrease or increase in circCHEK2 expression in tumors, respectively (Fig. 6e). Here, ADAR is linked to hepatocellular carcinoma.